159858-06-7

Basic information

• Product Name: N-[(Benzyloxy)carbonyl]-L-valyl-N₅-carbamoyl-L-ornithine
• Synonyms: N-[(Benzyloxy)carbonyl]-L-valyl-N₅-carbamoyl-L-ornithine
• CAS NO: 159858-06-7
• Molecular Weight: 408.455
• Mol File: 159858-06-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-[(Benzyloxy)carbonyl]-L-valyl-N₅-carbamoyl-L-ornithine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(Benzyloxy)carbonyl]-L-valyl-N₅-carbamoyl-L-ornithine(159858-06-7)
• EPA Substance Registry System: N-[(Benzyloxy)carbonyl]-L-valyl-N₅-carbamoyl-L-ornithine(159858-06-7)

Safety Data

• Hazardous Substances Data: 159858-06-7(Hazardous Substances Data)

Upstream product

• 3496-11-5 2,5-dioxopyrrolidin-1-yl (2S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanoate 
• 372-75-8 Citrulline 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 410093-14-0 Carbonic acid 4-[(S)-2-((S)-2-benzyloxycarbonylamino-3-methyl-butyrylamino)-5-ureido-pentanoylamino]-benzyl ester 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenyl ester 
• 410093-13-9 Carbonic acid (1S,2R)-2-acetylamino-1-phenyl-propyl ester 4-[(S)-2-((S)-2-benzyloxycarbonylamino-3-methyl-butyrylamino)-5-ureido-pentanoylamino]-benzyl ester 
• 410093-06-0 ((S)-2-Methyl-1-{(S)-1-[4-(naphthalen-1-yloxymethyl)-phenylcarbamoyl]-4-ureido-butylcarbamoyl}-propyl)-carbamic acid benzyl ester 

Downstream Products

• 916746-27-5 N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N⁵-carbamoyl-L-ornithine 
• 159858-08-9 benzyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 
• 159858-07-8 N-Cbz-Val-Cit-4-aminobenzyl alcohol 

Relevant articles and documents

ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin

A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepared as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs. Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.